Hepatitis Headlines

Lenvatinib Approved as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Lenvatinib Approved as First-Line Treatment for Unresectable Hepatocellular Carcinoma

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC.

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Hepatitis C virus-negative recipients of HCV-infected kidneys experience HCV cure and good quality of life.

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

The FDA has approved Mulpleta for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hepatitis B core Antibody (anti-HB c+) organs may be a safe and ethical transplant option in an era where increased medical knowledge has enabled greater treatment for hepatitis.

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

Meeting World Health Organization targets for chronic hepatitis B by 2030 will be cost-effective.

NFID Initiative Working to Up Hepatitis B Vaccination Rates

NFID Initiative Working to Up Hepatitis B Vaccination Rates

A new initiative to increase hepatitis B virus vaccination rates among at-risk adults has been developed.

Canada Updates Guidelines for Hepatitis C Virus Infection

Canada Updates Guidelines for Hepatitis C Virus Infection

The Canadian Medical Association provided an updated evidence-based recommendations for the treatment of patients with chronic hepatitis C virus.

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

The FDA has granted Fast Track designation to a novel antiviral in development for the treatment of HBV infection.

Blood-Brain Barrier Damage, Psychiatric Impairment in HCV Infection and Alcohol Abuse

Blood-Brain Barrier Damage, Psychiatric Impairment in HCV Infection and Alcohol Abuse

Alcohol use disorder in patients with HCV infection is associated with increased symptoms of depression and anxiety compared with patients with HCV and no history of alcohol abuse.

Universal Screening Best Strategy for Hepatitis C in France

Universal Screening Best Strategy for Hepatitis C in France

Universal screening is the most effective strategy for hepatitis C virus in France.

Sign Up for Free e-newsletters